We identified fibroblast-specific hyaluronan synthesis at the center of p38-driven tumorigenesis, which regulates early stromal fibroblast activation, the conversion to carcinoma-associated fibroblasts (CAFs), and cancer cell proliferation. We recognized fibroblast-specific hyaluronan synthesis at the center of p38-driven tumorigenesis, which regulates early stromal fibroblast activation, the conversion to carcinoma-associated fibroblasts (CAFs), and cancer cell proliferation. Systemic down-regulation of p38MAPK signaling in a knock-in model with substitution of activating Tyr182 to phenylalanine or conditional ablation of p38 in fibroblasts has a significant tumor-suppressive effect on K-ras lung tumorigenesis. Furthermore, bothKras-driven mouse lung tumors and orthotopically grown primary human being lung cancers show a significant sensitivity to both a chemical p38 inhibitor and an over-the-counter inhibitor of hyaluronan synthesis. We propose that p38MAPKhyaluronan-dependent reprogramming of the tumor microenvironment Mericitabine plays a critical role in driving lung tumorigenesis, while blocking this process could have far-reaching therapeutic implications. Cancer is a complex systemic disease in which many normal cells are recruited to the tumor site to sustain malignant growth (Junttila and de Sauvage 2013). The initial expansion of cancer cells produces a signal to create the cancer niche; however , it is not clear which type of normal cell responds first to the initial tumor growth. Evidence offers indicated that fibroblasts Mericitabine were among the first cells to be recruited by tumor cells; however , it is widely accepted that normal fibroblasts generally suppress tumor formation (Dotto et al. 1988; Junttila and de Sauvage 2013). To promote tumorigenesis, normal fibroblasts must be educated by cancer cells in the process of BIRC2 conversion to carcinoma-associated fibroblasts (CAFs) (Orimo et al. 2005). Once accomplished, this will result in extensive tissue remodeling (Joyce and Pollard 2009; Gascard and Tlsty 2016). Further establishment of a complex, dynamic network of cytokines, chemokines, growth factors, and matrix remodeling enzymes ultimately changes the physical and chemical properties of the tumor. Additionally , this dynamic tumor-promoting microenvironment is expanded by recruiting immune cells, pericytes, and sometimes adipocytes and establishing tumor vasculature and lymphatics. Lung cancer causes the largest number of cancer-related deaths globally. More than 85% of lung cancers are currently classified because non-small cell lung cancer (NSCLC), with a predicted 5-year survival rate of only 15. 9% (Chen et al. 2014). It becomes increasingly clear that the effective method of treating lung cancer will require therapies that can target both tumor cells and tumor-associated components. Stromal cells, such as fibroblasts, are known to provide signals to support tumor growth and survival, but no drug options exist that successfully target this component of the tumor microenvironment. p38MAPK (MAPK14) continues to be implicated in the regulation of diverse cancerous and noncancerous cell types that could be found in the tumor microenvironment (Alspach et al. 2014; Igea and Nebreda 2015). Originally, p38MAPK was proposed as a potential cancer suppressor (Brancho et al. 2003; Bulavin and Fornace 2004). However , its role in tumorigenesis has remained highly controversial. Initial experiments in mouse cancer models showed that p38MAPK suppressed lung and liver tumor formation in vivo (Hui et al. 2007; Ventura Mericitabine et al. 2007). However , enhanced p38MAPK activation and overexpression were reported in different human cancers, including lung tumors, and, in some cases, correlated with a poor prognosis (Greenberg et al. 2002; Elenitoba-Johnson et al. 2003; Pomerance et al. 2006). A definitive conclusion about the role of p38MAPK in cancer has been prevented by, among other reasons, the lack of models with systemic p38MAPK inactivation because conventional knockouts are embryonic-lethal (Adams et al. 2000; Tamura et al. 2000). Here we overcame this problem by substituting the p38MAPK-activating site Tyr182 with Phe. This genetic change resulted in significant down-regulation of p38MAPK signaling, and cancer cells carrying this mutation appeared to be more tumorigenic. In razor-sharp contrast, in a mouse model of Kras-driven tumorigenesis, this systemic inactivation of p38MAPK caused profound tumor resistance. This effect appeared to be non-cell-autonomous and independent of p53 and relied on p38MAPK activation in fibroblasts at the tumor site. == Results == == In silico network-based analysis identifies p38MAPK as a master NSCLC regulator == To determine novel, important molecular regulators in NSCLC pathogenesis, we constructed an in silico network of genes and interactions. We compiled transcriptomic data sets of cancer tissues and compared them with paired, noncancer control transcriptomic data sets (n= 60) from publically available databases (GSE19804). We called the Mericitabine complete network the expanded NSCLC network (Fig. 1A; Supplemental Table 1). Next, we ranked genes in accordance to a hypergeometric analysis from the number of NSCLC-relevant interactions, accounting for the expanded NSCLC network size and the total number of focuses on for each gene. The top-ranked genes would be expected to be highly influential in the context of NSCLC (a large betweenness centrality.
